Back to Search Start Over

Clinical Features and Treatment Outcomes of Langerhans Cell Histiocytosis

Authors :
Ho Joon Im
Ki Woong Sung
Hee Young Shin
Kyung Duck Park
Ji Won Lee
Jun Eun Park
Young-Ho Lee
Jin Kyung Suh
Chuhl Joo Lyu
Bin Cho
Jong Jin Seo
Hong Hoe Koo
Byung Kiu Park
Heung Sik Kim
Mee Jeong Lee
Meerim Park
Keon Hee Yoo
Joon Sup Song
Bo Eun Kim
Hack Ki Kim
Nak Gyun Chung
Hee Jo Baek
Kyung Ha Ryu
Hoon Kook
Jae Min Lee
Hoi Soo Yoon
Kwang Chul Lee
Hye Lim Jung
Hyeon Jin Park
Hyoung Jin Kang
Soon Ki Kim
Hwang Min Kim
Soo Hyun Lee
Sang Kyu Park
Yeon Jung Lim
Eun Sil Park
Jeong A Park
Young Tak Lim
Kyung Nam Koh
Eun Sun Yoo
Hyoung Soo Choi
Kun Soo Lee
Source :
Journal of Pediatric Hematology/Oncology. 36:125-133
Publication Year :
2014
Publisher :
Ovid Technologies (Wolters Kluwer Health), 2014.

Abstract

A nationwide survey was conducted to clarify the clinical features and outcomes of Korean children with Langerhans cell histiocytosis (LCH). Korea Histiocytosis Working Party analyzed the data of 603 patients who were diagnosed with LCH between 1986 and 2010 from 28 institutions in Korea. Median age at diagnosis was 65 months (range, 0 to 276 mo). Bone was the most frequently affected organ (79.6%) followed by skin (19.2%). Initially, 419 patients (69.5%) had single-system involvement (SS), 85 (14.1%) with multisystem (MS) disease without risk organ involvement (MS-RO), and 99 (16.4%) multisystem disease with risk organ involvement (MS-RO). The 5-year overall survival (OS) rates in the SS, MS-RO, and MS-RO groups were 99.8%, 98.4%, and 77.0%, respectively (P

Details

ISSN :
10774114
Volume :
36
Database :
OpenAIRE
Journal :
Journal of Pediatric Hematology/Oncology
Accession number :
edsair.doi.dedup.....eeaa84c37677ac35c0c193c448d75f30
Full Text :
https://doi.org/10.1097/mph.0000000000000054